Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART)
Status:
Completed
Trial end date:
2015-08-31
Target enrollment:
Participant gender:
Summary
This is a Phase 3, randomized, controlled, single-blind, multicenter, parallel-arm trial to
assess the safety and efficacy of Pergoveris® (recombinant human follicle stimulating hormone
[r-hFSH]/recombinant human luteinising hormone [r-hLH]) and GONAL-f® for multifollicular
development as part of an assisted reproductive technology (ART) treatment cycle in poor
ovarian responders, as aligned with the 2011 Consensus Meeting of the European Society of
Human Reproduction and Embryology (ESHRE) criteria.